AU2012278813B2 - Systems, methods, and formulations for treating cancer - Google Patents

Systems, methods, and formulations for treating cancer Download PDF

Info

Publication number
AU2012278813B2
AU2012278813B2 AU2012278813A AU2012278813A AU2012278813B2 AU 2012278813 B2 AU2012278813 B2 AU 2012278813B2 AU 2012278813 A AU2012278813 A AU 2012278813A AU 2012278813 A AU2012278813 A AU 2012278813A AU 2012278813 B2 AU2012278813 B2 AU 2012278813B2
Authority
AU
Australia
Prior art keywords
pharmaceutical formulation
quercetin
cancer
phenyl butyrate
sodium phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012278813A
Other languages
English (en)
Other versions
AU2012278813A1 (en
Inventor
Mohammad Nezami Md
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESEARCH CANCER INSTITUTE OF AMERICA
Original Assignee
Research Cancer Inst Of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Cancer Inst Of America filed Critical Research Cancer Inst Of America
Publication of AU2012278813A1 publication Critical patent/AU2012278813A1/en
Application granted granted Critical
Publication of AU2012278813B2 publication Critical patent/AU2012278813B2/en
Priority to AU2016269491A priority Critical patent/AU2016269491B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2012278813A 2011-07-07 2012-07-06 Systems, methods, and formulations for treating cancer Active AU2012278813B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016269491A AU2016269491B2 (en) 2011-07-07 2016-12-08 Systems, methods, and formulations for treating cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161505393P 2011-07-07 2011-07-07
US61/505,393 2011-07-07
US201161507950P 2011-07-14 2011-07-14
US61/507,950 2011-07-14
PCT/US2012/045821 WO2013006821A1 (en) 2011-07-07 2012-07-06 Systems, methods, and formulations for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016269491A Division AU2016269491B2 (en) 2011-07-07 2016-12-08 Systems, methods, and formulations for treating cancer

Publications (2)

Publication Number Publication Date
AU2012278813A1 AU2012278813A1 (en) 2014-01-30
AU2012278813B2 true AU2012278813B2 (en) 2016-09-08

Family

ID=47437478

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012278813A Active AU2012278813B2 (en) 2011-07-07 2012-07-06 Systems, methods, and formulations for treating cancer
AU2016269491A Active AU2016269491B2 (en) 2011-07-07 2016-12-08 Systems, methods, and formulations for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016269491A Active AU2016269491B2 (en) 2011-07-07 2016-12-08 Systems, methods, and formulations for treating cancer

Country Status (13)

Country Link
US (3) US20130011488A1 (enExample)
EP (2) EP3326625A1 (enExample)
JP (3) JP6082737B2 (enExample)
KR (2) KR102020939B1 (enExample)
CN (2) CN103796514A (enExample)
AU (2) AU2012278813B2 (enExample)
CA (1) CA2839727C (enExample)
ES (1) ES2630306T3 (enExample)
IN (1) IN2014DN00195A (enExample)
MX (1) MX354383B (enExample)
PL (1) PL2729008T3 (enExample)
RU (1) RU2644635C2 (enExample)
WO (1) WO2013006821A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
CA2861047A1 (en) * 2012-01-18 2013-07-25 Concert Pharmaceuticals, Inc. Deuterated alpha-lipoic acid
CN103877066B (zh) * 2014-02-21 2016-08-24 中国人民解放军第二军医大学 载多西他赛和莱菔硫烷的自组装纳米粒的制备方法与应用
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2018157081A1 (en) * 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) * 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
EP3691632B1 (en) * 2017-10-06 2025-01-01 Research Cancer Institute of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2020061254A1 (en) * 2018-09-19 2020-03-26 Virginia Tech Intellectual Properties, Inc. Brca1 modulating compounds, formulations thereof, and uses thereof
US20230008508A1 (en) * 2019-12-10 2023-01-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapies for the treatment of cancer
CN112336716A (zh) * 2020-11-25 2021-02-09 四川大学华西医院 维生素c和双硫仑在制备抗肿瘤联合用药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023179A2 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569836A (en) * 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
AU3257297A (en) * 1996-06-11 1998-01-07 Novartis Ag Combination of a somatostatin analogue and a rapamycin
US5865722A (en) 1997-04-04 1999-02-02 Numotech, Incorporated Shape-adaptable topical hyperbaric oxygen chamber
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6376525B1 (en) * 2000-09-15 2002-04-23 Qingzhong Kong Method and composition for treating cancer using cellular organelle crystallizing agents
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US6572897B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes
EP1571225A1 (en) * 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
EP2389930A1 (en) * 2006-03-31 2011-11-30 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control
EP1847274A1 (en) * 2006-04-21 2007-10-24 CIPROSA LLC - Corporate Creations Network, Inc. Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
WO2008011363A2 (en) * 2006-07-17 2008-01-24 Thomas Christian Lines Quercetin-containing compositions
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
US20080305096A1 (en) * 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
EP2306996A1 (en) * 2008-07-18 2011-04-13 Novartis AG Use of hdac inhibitors for the treatment of hodgkin's disease
US20100316733A1 (en) * 2009-06-15 2010-12-16 Locklear Kenneth R Hyperbaric Oxygen Therapy and Treatment Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023179A2 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mokrzycki. K. "Anti-atherosclerotic efficacy of quercetin and sodium phenylbutyrate in Rabbits" Ann Acad Med Stetin. 2000 Vol. 4 pages 189-200 *

Also Published As

Publication number Publication date
KR20140076546A (ko) 2014-06-20
JP6082737B2 (ja) 2017-02-15
AU2016269491B2 (en) 2018-08-30
CA2839727C (en) 2023-10-17
RU2644635C2 (ru) 2018-02-13
JP2014518274A (ja) 2014-07-28
KR102020939B1 (ko) 2019-09-11
MX354383B (es) 2018-03-02
JP2017105797A (ja) 2017-06-15
IN2014DN00195A (enExample) 2015-06-05
WO2013006821A1 (en) 2013-01-10
US20200206183A1 (en) 2020-07-02
PL2729008T3 (pl) 2017-10-31
EP2729008A1 (en) 2014-05-14
MX2014000150A (es) 2014-05-14
CN103796514A (zh) 2014-05-14
EP2729008B1 (en) 2017-04-05
EP3326625A1 (en) 2018-05-30
US20170014376A1 (en) 2017-01-19
JP2018203767A (ja) 2018-12-27
JP6401317B2 (ja) 2018-10-10
RU2014101261A (ru) 2015-08-20
CN109675041A (zh) 2019-04-26
AU2012278813A1 (en) 2014-01-30
US20130011488A1 (en) 2013-01-10
EP2729008A4 (en) 2014-10-29
CA2839727A1 (en) 2013-01-10
ES2630306T3 (es) 2017-08-21
KR20190107166A (ko) 2019-09-18
AU2016269491A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
AU2016269491B2 (en) Systems, methods, and formulations for treating cancer
US11890269B2 (en) Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
JP2008110996A (ja) 体脂肪低減用組成物
TW202333729A (zh) 組合
WO2020099926A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2019178023A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
CN120659608A (zh) 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
KR101695801B1 (ko) 운동 뉴런의 자가 포식 작용 억제를 위한 약학적 조성물 및 이의 용도
CN101797243B (zh) 一种含有左旋多巴和冰片的组合物及其应用
WO2014047782A1 (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2024213057A1 (zh) Lsd1抑制剂与药物联用治疗癌症的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)